Middle East & Africa Sglt2 Inhibitors Market Size & Outlook
Related Markets
MEA sglt2 inhibitors market highlights
- The MEA sglt2 inhibitors market generated a revenue of USD 729.5 million in 2024.
- The market is expected to grow at a CAGR of 3.8% from 2025 to 2033.
- In terms of segment, jardiance (empagliflozin) was the largest revenue generating drug in 2024.
- Other Drug is the most lucrative drug segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2025 to 2033.
MEA data book summary
| Market revenue in 2024 | USD 729.5 million |
| Market revenue in 2033 | USD 1,021.1 million |
| Growth rate | 3.8% (CAGR from 2025 to 2033) |
| Largest segment | Jardiance (empagliflozin) |
| Fastest growing segment | Other Drug |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Jardiance (Empagliflozin), Farxiga (Dapagliflozin), Invokana (Danagliflozin), Inpefa (Sotagliflozin), Qtern (Dapagliflozin/Saxagliptin), Other Drug |
| Key market players worldwide | Boehringer Ingelheim International GmbH, AstraZeneca PLC, Merck & Co., Inc., Johnson & Johnson Services, Inc., TheracosBio, Lexicon Pharmaceuticals, Eli Lilly and Company, Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Ltd. |
Other key industry trends
- In terms of revenue, MEA region accounted for 4.3% of the global sglt2 inhibitors market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 4,154.6 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
SGLT2 Inhibitors Market Scope
SGLT2 Inhibitors Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| TheracosBio | View profile | 1-10 | Framingham, Massachusetts, United States, North America | http://www.theracosbio.com |
| Lexicon Pharmaceuticals | View profile | 101-250 | The Woodlands, Texas, United States, North America | http://www.lexpharma.com |
| Glenmark Pharmaceuticals Ltd. | View profile | - | - | - |
| Boehringer Ingelheim International GmbH | View profile | - | - | - |
| Eli Lilly and Company | View profile | - | - | - |
| Merck & Co., Inc. | View profile | - | - | - |
| Johnson & Johnson Services, Inc. | View profile | - | - | - |
| Bristol-Myers Squibb Company | View profile | - | - | - |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
Middle East & Africa sglt2 inhibitors market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to sglt2 inhibitors market will help companies and investors design strategic landscapes.
Jardiance (empagliflozin) was the largest segment with a revenue share of 59.73% in 2024. Horizon Databook has segmented the Middle East & Africa sglt2 inhibitors market based on jardiance (empagliflozin), farxiga (dapagliflozin), invokana (danagliflozin), inpefa (sotagliflozin), qtern (dapagliflozin/saxagliptin), other drug covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to Middle East & Africa sglt2 inhibitors market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa sglt2 inhibitors market databook
-
Our clientele includes a mix of sglt2 inhibitors market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa sglt2 inhibitors market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa sglt2 inhibitors market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
MEA sglt2 inhibitors market size, by country, 2021-2033 (US$M)
Middle East & Africa SGLT2 Inhibitors Market Outlook Share, 2024 & 2033 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
